Stefanie Rauch

Stefanie Rauch

Auto-generated profile, based on publicly available information

Stefanie Rauch

Medical University of Innsbruck

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Antiviral Research
Verified
Journal Article
Open access
SRStefanie Rauch
Stefanie Rauch
FCFrancesco Costacurta
Francesco Costacurta
HSHelge Schöppe
Helge Schöppe
JPJu-Yi Peng
Ju-Yi Peng
DBDavid Bante
David Bante
EHEmmanuel Heilmann
Emmanuel Heilmann
In the SARS-CoV-2 pandemic, the so far two most effective approved antivirals are the protease inhibitors nirmatrelvir, in combination with ritonavir (Paxlovid) and ensitrelvir (Xocova). However, antivirals and indeed all antimicrobial drugs are sooner or later challenged by resistance mutations. Studying such mutations is essential for treatment decisions and pandemic preparedness. At the same time, generating resistant viruses to assess mutants is controversial, especially with pathogens of pandemic potential like SARS-CoV-2. To circumvent gain-of-function research with non-attenuated SARS-CoV-2, a previously developed safe system based on a chimeric vesicular stomatitis virus dependent on the SARS-CoV-2 main protease (VSV-Mpro) was used to select mutations against ensitrelvir. Ensitrelvir is clinically especially relevant due to its single-substance formulation, avoiding drug-drug interactions by the co-formulated CYP3A4 inhibitor ritonavir in Paxlovid. By treating VSV-Mpro with ensitrelvir, highly-specific resistant mutants against this inhibitor were selected, while being still fully or largely susceptible to nirmatrelvir. We then confirmed several ensitrelvir-specific mutants in gold standard enzymatic assays and SARS-CoV-2 replicons. These findings indicate that the two inhibitors can have distinct viral resistance profiles, which could determine treatment decisions.

25 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancesco Costacurta
Francesco Costacurta
ADAndrea Dodaro
Andrea Dodaro
DBDavid Bante
David Bante
HSHelge Schoeppe
Helge Schoeppe
BSBernhard Sprenger
Bernhard Sprenger
EHEmmanuel Heilmann
Emmanuel Heilmann
Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL pro /M pro ) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M pro resistance mutations, we passaged a previously developed, chimeric vesicular stomatitis virus (VSV-M pro ) with increasing, yet suboptimal concentrations of nirmatrelvir. Using Wuhan-1 and Omicron M pro variants, we selected a large set of mutants. Some mutations are frequently present in GISAID, suggesting their relevance in SARS-CoV-2. The resistance phenotype of a subset of mutations was characterized against clinically available PIs (nirmatrelvir and ensitrelvir) with cell-based and biochemical assays. Moreover, we showed the putative molecular mechanism of resistance based on in silico molecular modelling. These findings have implications on the development of future generation M pro inhibitors, will help to understand SARS-CoV-2 protease-inhibitor-resistance mechanisms and show the relevance of specific mutations in the clinic, thereby informing treatment decisions. Teaser: Understanding how SARS-CoV-2 could counter the antiviral drug nirmatrelvir and what it means for the future of COVID-19 treatment.

4 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LKLaura Krismer
Laura Krismer
HSHelge Schöppe
Helge Schöppe
SRStefanie Rauch
Stefanie Rauch
DBDavid Bante
David Bante
BSBernhard Sprenger
Bernhard Sprenger
EHEmmanuel Heilmann
Emmanuel Heilmann
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an epidemic, zoonotically emerging pathogen initially reported in Saudi Arabia in 2012. MERS-CoV has the potential to mutate or recombine with other coronaviruses, thus acquiring the ability to efficiently spread among humans and become pandemic. Its high mortality rate of up to 35 % and the absence of effective targeted therapies call for the development of antiviral drugs for this pathogen. Since the beginning of the SARS-CoV-2 pandemic, extensive research has focused on identifying protease inhibitors for the treatment of SARS-CoV-2. Our intention was therefore to assess whether these protease inhibitors are viable options for combating MERS-CoV. To that end, we used previously established protease assays to quantify inhibition of the SARS-CoV-2 and MERS-CoV main proteases. Furthermore, we selected MERS-CoV-M pro mutants resistant against nirmatrelvir, the most effective inhibitor of this protease, with a safe, surrogate virus-based system, and suggest putative resistance mechanisms. Notably, nirmatrelvir demonstrated effectiveness against various viral proteases, illustrating its potential as a broad-spectrum coronavirus inhibitor. To adress the inherent resistance of MERS-CoV-M pro to ensitrelvir, we applied directed mutagenesis to a key ensitrelvir-interacting residue and provided structural models. One-Sentence Summary: We investigate antivirals for MERS-CoV with a pool of SARS-CoV-2 antiviral drugs and study potential resistances developing against those drugs.

23 December 2024 in Current Protocols
Verified
Journal Article
Open access
FCFrancesco Costacurta
Francesco Costacurta
SRStefanie Rauch
Stefanie Rauch
DLDorothee von Laer
Dorothee von Laer
EHEmmanuel Heilmann
Emmanuel Heilmann
Antiviral drugs are essential medications to save the lives of infected people. However, they are under constant threat to become ineffective as viruses evolve quickly. Studying the development of resistance is therefore paramount to understand the impact of mutations on pharmacological treatment and to make informed decisions. Yet, such studies are open to scrutiny, as they are considered gain‐of‐function research, which is especially problematic with viruses of pandemic potential. In this article, we present a protocol that allows for the selection of antiviral resistance mutations safely, without using the actual virus (e.g., SARS‐CoV‐2, MERS‐CoV). Instead, we use vesicular stomatitis virus (VSV) that serves as a surrogate virus; like other RNA viruses, it is prone to mutations due to its polymerase lacking proofreading. By replacing parts of the VSV genome with transgenes from other viruses, VSV becomes dependent on their function. Thus, we can mount a selection pressure with antivirals targeting the transgenes to subsequently sequence selected resistance mutations. This article provides a protocol for this process as well as a sequencing pipeline that we used to collect mutations. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol: Using VSV as a platform for directed protease evolutionAlternate Protocol: Dose response assay with TCID50 readoutSupport Protocol 1: A pipeline for high‐throughput VSV sequencingSupport Protocol 2: Rescue of VSV

21 November 2024 in Current Protocols
Verified
Journal Article
Open access
SRStefanie Rauch
Stefanie Rauch
FCFrancesco Costacurta
Francesco Costacurta
DLDorothee von Laer
Dorothee von Laer
EHEmmanuel Heilmann
Emmanuel Heilmann
Protease inhibitors are among the most powerful antiviral drugs. They have been used successfully against viruses, such as the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Protease inhibitor screening tools are therefore important to identify inhibitors that have the potential to become antiviral drugs. In this article, we describe newly developed cell‐ and virus replicon‐based platforms to screen inhibitors. We developed the methods presented here by genetically modifying vesicular stomatitis virus, a model virus from the family Rhabdoviridae. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol: Mpro‐On and ‐Off assayAlternate Protocol 1: Virus production with transient P‐ and L TransIT transfectionAlternate Protocol 2: Virus production with transient P‐ and L Ca2PO4 transfectionAlternate Protocol 3: Luciferase‐based variation of the On assayAlternate Protocol 4: Screening assay with fluorescence‐activated cell sorting readoutSupport Protocol: Performing kinetic measurements with Off assay

8 January 2026 in bioRxiv
Verified
Preprint
Open access
FCFrancesco Costacurta
Francesco Costacurta
ADAndrea Dodaro
Andrea Dodaro
AFAlbert Falch
Albert Falch
SRStefanie Rauch
Stefanie Rauch
JRJakob Riccabona
Jakob Riccabona
EHEmmanuel Heilmann
Emmanuel Heilmann
Antivirals are life-saving medications. However, pathogens develop resistances, mitigating their effect. Resistance studies (gain-of-function, GOF) are therefore paramount before and while antivirals are used clinically to characterize resistances and ideally study how to counteract them with other antivirals. The ability to switch from one antiviral, against which the virus is resistant, to another, depends on the availability of alternative drugs. Furthermore, targeting different parts of the virus synergistically with multiple drugs decreases the odds of simultaneous resistance. However, studying resistance, cross-resistance and remaining susceptibility requires working with the actual pathogen. Especially when introducing resistances into dangerous viruses, performing GOF studies would raise safety concerns and require firm biological containment. In this study we developed a novel dual-chimeric virus encoding both SARS-CoV-2 spike glycoprotein and main protease (Mpro) based on the model virus, vesicular stomatitis virus (VSV). We applied selection pressure with spike and Mpro inhibitors, generated mutants of these viruses and determined their resistance and cross-resistance profiles by performing dose-response experiments with live and pseudotyped viruses. Additionally, we conducted in silico calculations to determine the impact of spike substitutions to the observed resistance phenotype. With the new technology presented here, we demonstrate that it is possible to carry out GOF studies more safely and highlight their importance in the future challenges of virological research.